Cyclosporine-associated thrombotic microangiopathy during daclizumab induction: a suggested therapeutic approach.
Trimarchi, H
Cyclosporine-associated thrombotic microangiopathy during daclizumab induction: a suggested therapeutic approach. [electronic resource] - Nephron Apr 2001 - 361-4 p. digital
Publication Type: Case Reports; Journal Article
1660-8151
10.1159/000045943 doi
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Biomarkers--blood
Blood Component Transfusion
Cyclosporine--adverse effects
Daclizumab
Drug Therapy, Combination
Female
Fibrin Fibrinogen Degradation Products--analysis
Hemolysis
Humans
Immunoglobulin G--therapeutic use
Immunosuppressive Agents--adverse effects
Kidney Failure, Chronic--etiology
Kidney Transplantation--immunology
Living Donors
Male
Microcirculation--pathology
Middle Aged
Plasmapheresis
Polycystic Kidney Diseases--complications
Tacrolimus--therapeutic use
Thrombosis--chemically induced
Cyclosporine-associated thrombotic microangiopathy during daclizumab induction: a suggested therapeutic approach. [electronic resource] - Nephron Apr 2001 - 361-4 p. digital
Publication Type: Case Reports; Journal Article
1660-8151
10.1159/000045943 doi
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Biomarkers--blood
Blood Component Transfusion
Cyclosporine--adverse effects
Daclizumab
Drug Therapy, Combination
Female
Fibrin Fibrinogen Degradation Products--analysis
Hemolysis
Humans
Immunoglobulin G--therapeutic use
Immunosuppressive Agents--adverse effects
Kidney Failure, Chronic--etiology
Kidney Transplantation--immunology
Living Donors
Male
Microcirculation--pathology
Middle Aged
Plasmapheresis
Polycystic Kidney Diseases--complications
Tacrolimus--therapeutic use
Thrombosis--chemically induced